Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme - GENZ -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (4)	7/8/2007 8:24:22 AM
From: tom pope	Respond to of 10

ML brushes the failure aside. If they're right, it is an interesting buy: Tolevamer misses endpoint; Use weakness to BUY Genzyme reported today that its first phase III trial of tolevamer, for the treatment of Clostridium difficile associated diarrhea, did not meet its primary endpoint of non-inferiority to Vancomycin. While GENZ plans to finish its second phase III, we have removed tolevamer from our models. We had projected peak sales of $250 MM by 2015. We have also removed expenses related to building a sales force for the drug, which we estimated at ~ $18 MM in 2010. We expect Mozobil data to be coming shortly. We reiterate our BUY rating on today's weakness.